Total Payments
$78,176
2024 Payments
$2,042
Companies
25
Transactions
116
Medicare Patients
1,240
Medicare Billing
$171,633
Payment Breakdown by Category
Other$44,305 (56.7%)
Consulting$19,713 (25.2%)
Travel$6,488 (8.3%)
Research$3,770 (4.8%)
Food & Beverage$3,465 (4.4%)
Education$435.34 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,405 | 15 | 53.0% |
| Consulting Fee | $19,713 | 8 | 25.2% |
| Travel and Lodging | $6,488 | 20 | 8.3% |
| Unspecified | $3,770 | 1 | 4.8% |
| Food and Beverage | $3,465 | 63 | 4.4% |
| Honoraria | $2,900 | 2 | 3.7% |
| Education | $435.34 | 7 | 0.6% |
Payments by Type
General
$74,406
115 transactions
Research
$3,770
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47,917 | 54 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $7,944 | 15 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $6,270 | 3 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $4,019 | 9 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,930 | 3 | $0 (2022) |
| AbbVie, Inc. | $2,363 | 1 | $0 (2017) |
| Catalyst Pharmaceuticals, Inc. | $1,758 | 3 | $0 (2023) |
| G1 Therapeutics, Inc. | $1,500 | 1 | $0 (2022) |
| Daiichi Sankyo Inc. | $1,058 | 1 | $0 (2024) |
| Puma Biotechnology, Inc. | $1,000 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,042 | 16 | Daiichi Sankyo Inc. ($1,058) |
| 2023 | $2,095 | 16 | Catalyst Pharmaceuticals, Inc. ($1,758) |
| 2022 | $3,886 | 9 | AstraZeneca Pharmaceuticals LP ($2,219) |
| 2021 | $189.09 | 5 | Janssen Biotech, Inc. ($90.00) |
| 2020 | $3,896 | 5 | Takeda Pharmaceuticals U.S.A., Inc. ($2,850) |
| 2019 | $11,376 | 10 | Merck Sharp & Dohme Corporation ($7,575) |
| 2018 | $24,527 | 28 | Merck Sharp & Dohme Corporation ($18,755) |
| 2017 | $30,165 | 27 | Merck Sharp & Dohme Corporation ($21,251) |
All Payment Transactions
116 individual payment records from CMS Open Payments — Page 2 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/01/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $25.19 | General |
| Category: ONCOLOGY | ||||||
| 08/03/2023 | Catalyst Pharmaceuticals, Inc. | FIRDAPSE (Drug) | Honoraria | Cash or cash equivalent | $1,400.00 | General |
| Category: NEUROLOGY | ||||||
| 08/03/2023 | Catalyst Pharmaceuticals, Inc. | FIRDAPSE (Drug) | Travel and Lodging | Cash or cash equivalent | $143.27 | General |
| Category: NEUROLOGY | ||||||
| 07/27/2023 | Catalyst Pharmaceuticals, Inc. | FIRDAPSE (Drug) | Food and Beverage | Cash or cash equivalent | $215.19 | General |
| Category: NEUROLOGY | ||||||
| 07/27/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: Oncology | ||||||
| 06/08/2023 | Lilly USA, LLC | RETEVMO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: Oncology | ||||||
| 04/13/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $26.25 | General |
| Category: ONCOLOGY | ||||||
| 12/27/2022 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $1,942.50 | General |
| Category: Oncology | ||||||
| 12/16/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2022 | G1 Therapeutics, Inc. | COSELA (Drug) | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2022 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $120.80 | General |
| 11/15/2022 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $155.84 | General |
| 08/04/2022 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $32.62 | General |
| Category: Oncology | ||||||
| 06/30/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: ONCOLOGY | ||||||
| 05/25/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Education | In-kind items and services | $79.99 | General |
| 01/27/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.22 | General |
| Category: ONCOLOGY | ||||||
| 08/03/2021 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Education | In-kind items and services | $90.00 | General |
| Category: Oncology | ||||||
| 07/21/2021 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 02/02/2021 | Epizyme, Inc., | TAZVERIK (Drug) | Education | In-kind items and services | $45.00 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2020 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Consulting Fee | Cash or cash equivalent | $1,425.00 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2020 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Consulting Fee | Cash or cash equivalent | $1,425.00 | General |
| Category: ONCOLOGY | ||||||
| 09/29/2020 | Puma Biotechnology, Inc. | NERLYNX (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $3,770 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 266 | 596 | $192,955 | $42,778 |
| 2022 | 7 | 349 | 637 | $213,590 | $45,978 |
| 2021 | 6 | 323 | 621 | $206,750 | $46,327 |
| 2020 | 5 | 302 | 601 | $180,450 | $36,550 |
Total Patients
1,240
Total Services
2,455
Medicare Billing
$171,633
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 159 | 474 | $151,680 | $34,053 | 22.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 28 | 28 | $16,940 | $3,961 | 23.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 52 | 64 | $13,760 | $3,049 | 22.2% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 15 | 15 | $4,425 | $1,009 | 22.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 12 | 15 | $6,150 | $706.86 | 11.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 139 | 319 | $102,080 | $24,654 | 24.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 81 | 152 | $62,320 | $9,869 | 15.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 26 | 26 | $15,730 | $3,946 | 25.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 53 | 76 | $16,340 | $3,583 | 21.9% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 26 | 27 | $7,965 | $2,209 | 27.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 21 | $4,515 | $1,220 | 27.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 13 | 16 | $4,640 | $496.15 | 10.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 106 | 266 | $85,120 | $20,503 | 24.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 91 | 191 | $73,900 | $14,091 | 19.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 25 | 25 | $15,125 | $3,452 | 22.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 54 | 70 | $15,050 | $3,381 | 22.5% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 32 | 34 | $10,030 | $2,790 | 27.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 15 | 35 | $7,525 | $2,109 | 28.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 152 | 401 | $128,320 | $23,083 | 18.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 45 | 66 | $10,890 | $4,378 | 40.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 29 | 29 | $17,545 | $4,003 | 22.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 63 | 91 | $19,565 | $3,882 | 19.8% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 13 | 14 | $4,130 | $1,205 | 29.2% |
About Dr. Hamid Mirshahidi, M.D
Dr. Hamid Mirshahidi, M.D is a Medical Oncology healthcare provider based in Loma Linda, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659307015.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hamid Mirshahidi, M.D has received a total of $78,176 in payments from pharmaceutical and medical device companies, with $2,042 received in 2024. These payments were reported across 116 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($41,405).
As a Medicare-enrolled provider, Mirshahidi has provided services to 1,240 Medicare beneficiaries, totaling 2,455 services with total Medicare billing of $171,633. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Loma Linda, CA
- Active Since 06/25/2006
- Last Updated 05/04/2009
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1659307015
Products in Payments
- KEYTRUDA (Biological) $47,917
- ALUNBRIG (Drug) $9,120
- TAGRISSO (Drug) $7,572
- ZYKADIA (Drug) $3,896
- FIRDAPSE (Drug) $1,758
- COSELA (Drug) $1,500
- NERLYNX (Drug) $1,000
- IMBRUVICA (Drug) $213.98
- Defitelio (Drug) $120.42
- ADCETRIS (Biological) $57.73
- KRAZATI (Drug) $46.51
- KISQALI (Drug) $45.97
- TAZVERIK (Drug) $45.00
- IDHIFA (Drug) $43.44
- Trodelvy (Drug) $42.32
- SARCLISA (Biological) $26.59
- PIQRAY (Drug) $25.10
- INC280 (Drug) $20.37
- XPOVIO (Drug) $17.95
- RETEVMO (Drug) $17.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.